Micafungin Teva (Micafungin)

• Micafungin is an echinocandin antifungal indicated for the following clinical situations:
• Invasive candidiasis: provides effective treatment of bloodstream and deep‑tissue Candida infections, reducing mortality in adult and pediatric patients.
• Esophageal candidiasis: eradicates Candida infection of the esophagus in immunocompromised patients, improving swallowing function and nutritional intake.
• Prophylaxis in hematopoietic stem cell transplantation: prevents Candida infections during the neutropenic phase, supporting engraftment and reducing infection‑related complications.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesis of β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By disrupting cell‑wall construction, the drug leads to osmotic instability and cell lysis, selectively targeting fungi while sparing human cells. The inhibition is concentration‑dependent and does not affect mammalian glucan pathways, resulting in a favorable safety profile. Micafungin is administered intravenously, allowing rapid achievement of therapeutic plasma concentrations.

Micafungin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Elevated liver enzymes (ALT, AST): mild to moderate increases observed.
• Fever: transient temperature rise during therapy.
• Nausea: occasional gastrointestinal discomfort.
• Headache: mild headache reported in some patients.

Serious or Rare Side Effects

• Hypersensitivity reactions: rash, pruritus, or anaphylaxis may occur.
• Severe hepatic dysfunction: marked elevation of transaminases or bilirubin.
• Renal impairment: rare cases of increased serum creatinine.

When using Micafungin, clinicians should consider several precautionary measures to ensure safe administration.

• Renal function: assess baseline renal status; dose adjustment may be required in severe impairment.
• Hepatic function: monitor liver enzymes during treatment, especially in patients with pre‑existing liver disease.
• Drug interactions: review concomitant medications for potential major or moderate interactions.
• Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited.
• Infusion reactions: monitor for signs of fever, chills, or hypotension during IV administration.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Rifampin: strong enzyme inducer that may markedly reduce micafungin plasma concentrations.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may decrease exposure and compromise efficacy.
• Concurrent use with other echinocandins: increased risk of additive toxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole, voriconazole): may increase micafungin levels; monitor for toxicity.
• Immunosuppressants (e.g., tacrolimus, cyclosporine): possible altered concentrations; adjust dosing as needed.
• Warfarin: may enhance anticoagulant effect; monitor INR.